stockrowWarby Parker Inc.
WRBY Healthcare Medical Instruments & Supplies
Warby Parker Inc.’s revenue for fiscal 2025 (year ended December 2025) was $871.9 million, up 13.0% from fiscal 2024.
- Revenue
- +10.4%
- EPS
- −20.0%
- Free cash flow
- −30.3%
Quarter to September 2026, against a year earlier
Follow WRBY
Alert me
Warby Parker Inc. (WRBY) EBITDA
Warby Parker Inc.'s EBITDA for fiscal 2025 was $48.3M, up 148.5% from $19.5M in fiscal 2024. Over the twelve months to 30 June 2026 it was $59.0M. Over the past ten years it has ranged from −$122.1M (fiscal 2021) to $48.3M (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 4 consecutive fiscal years. Warby Parker Inc. ranks 23rd of 47 Medical Instruments & Supplies companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $48.3M | 148.49% |
| FY2024 | $19.5M | — |
| FY2023 | −$30.5M | — |
| FY2022 | −$79.1M | — |
| FY2021 | −$122.1M | — |
| FY2020 | −$37.9M | — |
| FY2019 | $12.9M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $18.3M | 11.07% |
| Mar 2026 | $16.5M | 126.58% |
| Dec 2025 | $7.3M | (57.29%) |
| Sep 2025 | $17.0M | 95.18% |
| 21 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| XRAY DENTSPLY SIRONA Inc. compare | $408.0M |
| STVN Stevanato Group S.p.A. compare | $351.1M |
| ICUI ICU Medical, Inc. compare | $314.2M |
| LMAT LeMaitre Vascular, Inc. compare | $88.7M |
| WRBY Warby Parker Inc. | $59.0M |
| ATRC AtriCure, Inc. compare | $34.2M |
| AZTA Azenta, Inc. compare | $28.1M |
| PLSE Pulse Biosciences, Inc compare | −$82.0M |
| KMTS Kestra Medical Technologies, Ltd. compare | −$133.4M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on WRBY
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement